2nd November 2018 - Upperton Exhibits at AAPS PharmSci360

Written on 02 November 2018.

Upperton Pharma Solutions will be exhibiting at AAPS PharmSci360 for the first time, with this year’s event running from November 5th – 7th in Washington, D.C.

· CEO & Founder Dr Richard Johnson and Business Development Executive Annette Kleiser will be available at booth 1643 to discuss how Upperton can support your development programme from early feasibility to clinical trials manufacturing

· Richard will also be presenting a scientific poster titled “Developing Cold Chain Independent Vaccines - Spray-drying of Virosomes to Produce Dry Powder Formulations”, on Tuesday 6th November

· This presentation will be based on the work of the MACIVIVA project which has the end goal of producing pioneering virosome-based vaccines against life threatening dise ases

Find Richard at Booth 1643 or arrange a meeting by contacting us.

26 September 2018 - Upperton Welcomes New Staff

Written on 26 September 2018.

Through extending our capabilities Upperton’s family have grown from three members of staff four years ago, to twenty-one staff this year. The latest staff updates are:

· Paul Kelsall, Director of Clinical Trials Manufacturing

Bringing experience in both sterile and non-sterile manufacturing, formulation development and facilities management. Paul formerly worked for Boots, Reckitt Benkiser, Nova Laboratories and Aesica.

· Sarah Bayliss, Director of Quality & Compliance

Experience of implementing, maintaining and remediating quality management systems. Sarah joins us from Aesica.

· Thomas Williams, Head of Clinical Manufacturing

Experience in developing and manufacturing investigational medicinal products for Phase I and II clinical trials. Thomas joins us from Quotient Sciences.

· Rebecca Gray, Senior QC Analyst

Experience in QC testing, early formulation development analysis and analytical method qualification. Rebecca joins us from Quotient Sciences.

· Klara Fisken, Business Development Associate

Klara joins us from the University of Nottingham, where she has just completed an MSc in Biopharmaceutical Biotechnology and Entrepreneurship.

· Ella Rose, Junior Project Scientist

Ella joins us from Nottingham Trent University as a year long placement student, where she is currently studying towards a BSc in Chemistry.

19th September 2018 - Extended Pilot Plant Capabilities

Written on 19 September 2018.

Our newly expanded Pilot Plant has enabled us to provide our customers with a seamless transfer of processes from laboratory to clinical trials manufacture. In particular we offer three scales of spray dryer, all of which can also be operated in our GMP plant. Spray dryers in our pilot plant include:

· ProCepT 4M8-TriX spray dryer

· Intermediate spray dryer (Upperton design)

· Niro Mobile Minor

These spray driers can spray dry a range of batch sizes (from 10mg to 3kg), allowing Upperton to conduct feasibility studies at scale to enable rapid transfer and reduce risk on scale up.

30th August 2018 - Successful First Batches from Upperton Clinical Manufacturing Plant

Written on 30 August 2018.

Successful First Batches from Upperton Clinical Manufacturing Plant

Upperton has successfully produced its first batches of product from its clinical manufacturing plant during August.

The inaugural batches were:

· Spray dried from solutions containing a range of excipients.

· Spray dried powder was both filled into capsules and tableted.

· Analytical tests including particle sizing, hardness and dissolution testing were performed.

The Upperton GMP manufacturing team were delighted to successfully complete these initial batches and now look forward to further work for an expanding customer base. To initiate discussions and learn more contact Upperton.

6th July 2018 - Upperton adds Mass Spectroscopy to its analytical capabilities

Written on 06 July 2018.

Upperton adds Mass Spectroscopy to its analytical capabilities

Upperton Pharma Solutions has now completed the installation and commissioning of its Agilent 1100 series LC/MSD (Liquid Chromatography mass selective detector) with ESI (Electrospray ionisation). The new capability will allow Upperton to offer clients molecular mass analysis, useful for assessing purity and detecting API decomposition or modification during formulation processing.

Contact Upperton and discuss how we can use this technique to characterise your API before, during and after formulation and dosage form development

1st June 2018 - 9th International GI-Targeting Seminar

Written on 01 June 2018.

Upperton will be attending the 9th International GI-Targeting Seminar hosted by Evonik in Darmstadt, Germany This 2-days seminar takes place between June 6-7, 2018 and offers attendees hands-on practical sessions in the Evonik laboratories.

21st May 2018 - APS Regulatory Essentials Conference

Written on 21 May 2018.

Upperton Pharma Solutions we will be attending the APS Regulatory Essentials Conference in Loughborough 22nd-23rd May. If you are there, talk to us about your GMP Spray drying requirements

14th March 2018 - Upperton Pharma Solutions to offer cGMP spray drying and clinical trials manufacturing service

Written on 14 March 2018.

Upperton Pharma Solutions is pleased to announce that the company has relocated to larger, self-contained facilities at Highfields Science Park, adjacent to the University of Nottingham. The move to new premises underlines the company’s rapid expansion and will enable it to develop its own cGMP manufacturing capabilities for early phase clinical trials.

The 15,000 square foot facility will house all of the company’s R&D team, as well as its fast-growing Quality Assurance and Manufacturing departments. Within the building is a clean room suite suitable for cGMP manufacture, and a pilot plant for non-GMP intermediate scale manufacturing. Upperton plans to have an MHRA licence for clinical trials manufacturing by Q3 of 2018.

The relocation and expansion will allow the company to offer a full integrated pharmaceutical development service, from early feasibility studies through to cGMP manufacture to support clinical trials. The extended range of capabilities includes:

cGMP manufacturing for clinical trials, release testing and QP release
Range of additional powder handling and filling capabilities
Enhanced dosage form development service
Expanded analytical service

In the coming weeks we will be sharing more news about our move and the new services we will be offering our customers.

Upperton R&D Director to speak at Spray Drying Conference on 20th-22nd March 2018

Written on 16 January 2018.

Upperton will be presenting at Spray Drying and Atomisation of Formulations the University of Leeds 20-22nd March 2018 at Faculty of Engineering, Leeds University. The course is the UK’s leading conference dedicated to the science and engineering of spray drying The talk entitled “Spray Drying of Pharmaceuticals” will be given by Dr Andrew Naylor on the 21st March 2018

EuroNanoForum 2017, Malta, 21st-23rd June

Written on 09 June 2017.

The conference will focus on how nano and materials technologies can strengthen competitiveness across all European industries.

News